October 2006
Worldwide Biotech;Oct2006, Vol. 18 Issue 10, p8
Trade Publication
The article reports on the screening conducted by Astellas Pharma Inc. against another target from Metabolex's proprietary database of human genes associated with insulin resistance and obesity in order to identify potential drug candidates. It presents the views of Harold E. Van Wart, president and chief executive officer of Metabolex, on the screening. Astellas and Metabolex have launched a research and drug discovery collaboration with the goal of identifying candidate compounds from drug targets.


Related Articles

  • New treatments for obesity and OAB. Coleman, Craig I. // Drug Topics;Sep2012, Vol. 156 Issue 9, p42 

    The article evaluates two drugs for treating obesity and overactive bladder (OAB) including the Belviq from Arena Pharmaceuticals Inc. and Myrbetriq, the mirabegron extended-release tablets from Astellas Pharma US Inc.

  • Common genetic variation near MC4R is associated with waist circumference and insulin resistance. Chambers, John C.; Elliott, Paul; Zabaneh, Delilah; Zhang, Weihua; Yun Li; Froguel, Philippe; Balding, David; Scott, James; Kooner, Jaspal S. // Nature Genetics;Jun2008, Vol. 40 Issue 6, p716 

    We carried out a genome-wide association study (318,237 SNPs) for insulin resistance and related phenotypes in 2,684 Indian Asians, with further testing in 11,955 individuals of Indian Asian or European ancestry. We found associations of rs12970134 near MC4R with waist circumference (P = 1.7...

  • New & Noteworthy: Fast-acting, Simple Dosing Stress Agent. Valenza, Tor // Imaging Economics;Jan2010, Vol. 23 Issue 1, p10 

    The article evaluates the pharmacologic stress agent Lexiscan from Astellas Pharma US Inc.

  • Astellas Pharma Completes Headquarters for the Americas Facility. Stratton, Kelly // National Real Estate Investor Exclusive Insight;6/12/2012, p10 

    The article discusses the completion of the build-to-suit project undertaken by GlenStar Properties LLC for the new corporate office of Astellas Pharma U.S. Inc. at the Headquarters for the Americas building in Northbrook, Illinois.

  • Conivaptan now available in single-use, premixed formulation. Nashed, Mona // Drug Topics;1/5/2009, Vol. 153 Issue 1, pH6 

    The article evaluates the Vaprisol conivaptan hydrochloride injection from Astellas Pharma US Inc.

  • Growing bio tech in Westchester. Philippidis, Alex // Westchester County Business Journal;8/9/2010, Vol. 49 Issue 32, p4 

    In this article the author reflects on the growth of biotechnology in Westchester, New York. He notes the disappointment expressed over the move of drug maker Astellas Pharma U.S. Inc. from Long Island to Ardsley Park campus in Greenburgh, especially among those who want to see higher-wage...

  • Astellas Pharma US, Inc., Announces New Science WoRx Program.  // NSTA Express;2/22/2010, p4 

    The article focuses on the company Astellas Pharma US Inc., which offers Science WoRx program which enhances the science education and provide resources to engage the students.

  • Evaluating the Role of LPIN1 Variation in Insulin Resistance, Body Weight, and Human Lipodystrophy in U.K. Populations. Fawcett, Katherine A.; Grimsey, Neil; Loos, Ruth J. F.; Wheeler, Eleanor; Daly, Allan; Soos, Maria; Semple, Robert; Syddall, Holly; Cooper, Cyrus; Siniossoglou, Symeon; O'Rahilly, Stephen; Wareham, Nicholas J.; Barroso, InĂªs // Diabetes;Sep2008, Vol. 57 Issue 9, p2527 

    OBJECTIVE--Loss of lipin 1 activity causes lipodystrophy and insulin resistance in the fld mouse, and LPIN1 expression and common genetic variation were recently suggested to influence adiposity and insulin sensitivity in humans. We aimed to conduct a comprehensive association study to clarify...

  • Antipsychotics tied to adiposity, insulin resistance in children. Foster, Melissa // Endocrine Today;Nov2011, Vol. 9 Issue 11, p18 

    The article focuses on a study which examined the association between antipsychotics use and adiposity and insulin sensitivity.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics